Arthur Donohue-Rolfe

Title: Innovations of Arthur Donohue-Rolfe

Introduction

Arthur Donohue-Rolfe is a notable inventor based in Maynard, MA (US). He has made significant contributions to the field of medical science, particularly in the development of therapeutic antibodies. With a total of 3 patents to his name, his work focuses on addressing critical health issues.

Latest Patents

Donohue-Rolfe's latest patents include groundbreaking innovations in the treatment of hemolytic uremic syndrome (HUS). One of his patents discloses humanized neutralizing antibodies derived from a transgenic mouse, along with a therapeutic method for treating individuals affected by HUS. This method involves administering monoclonal antibodies to patients in need of treatment or protection. Another patent details human and humanized monoclonal antibodies that specifically bind to subunit A of Shiga-like toxin II. These antibodies are effective in preventing or ameliorating symptoms of HUS in humans, with preferred dosages ranging from approximately 0.1 to 5.0 mg of antibody per kg of patient weight. The administration of these antibodies is typically transfused over a period of two hours, depending on the patient's condition.

Career Highlights

Arthur Donohue-Rolfe is affiliated with Tufts College, where he continues to advance his research and innovations. His work has the potential to significantly impact the treatment of HUS, a serious condition that can lead to kidney failure and other complications.

Collaborations

Throughout his career, Donohue-Rolfe has collaborated with esteemed colleagues such as Saul Tzipori and Ramaswamy Balakrishnan. These partnerships have contributed to the success and development of his innovative research.

Conclusion

Arthur Donohue-Rolfe's contributions to the field of medical science through his patents and research are commendable. His work in developing therapeutic antibodies for hemolytic uremic syndrome showcases his dedication to improving patient outcomes.